 SYDNEY, Australia, Nov. 19, 2020 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP announces it is advancing clinical development for its lead product candidate eftilagimod alpha efti or IMP321 through the expansion of its ongoing TACTI-002 study and a new Phase II trial. 